Thetford Mines, Quebec – December 4, 2018 – KDA Group Inc. (TSXV: KDA) (“KDA” or the “Corporation”) is proud to announce that it has signed a letter of intent (“LOI”) with Strides Pharma Global Pte Ltd. (“Strides”) for the sales of a majority stake in Pharmapar Inc. (“Pharmapar”), a division of KDA

Thetford Mines, Quebec – July 3, 2018 – KDA Group Inc. (TSXV: KDA) (“KDA Group” or the “Corporation”) is proud to announce that it has signed an agreement for the acquisition of 51% of CanNorth Medic Inc.

Thetford Mines, June 1st, 2018 – KDA Group Inc. (TSXV: KDA) (“KDA Group” or the “Corporation”) is proud to announce an agreement with ZoomMed Inc. (TSXV: ZMD) (“ZoomMed”) whereby KDA Group can distribute under a non-exclusive license the ZRx Prescriber developed by ZoomMed in the United States.

Thetford Mines, March 9, 2018 – KDA Group Inc. (TSXV: KDA) (“KDA Group” or the “Corporation”) announced today that it has accepted the resignation of its Chief Financial Officer, Mr. Bruno Dumais, effective immediately. Mr. Dumais is leaving the Corporation to pursue other interests. In the interim, Mr. Michael Kinley, Chairman of the Audit Committee, will assume theresponsibilities of Chief Financial Officer.

Thetford Mines, January 31, 2018 – KDA Group Inc. (TSXV: KDA) (“KDA Group” or the “Corporation”) is pleased to announce that it has completed a non-brokered private placement with accredited investors totaling 542 857 units

Thetford Mines, January 24, 2018 – KDA Group Inc. (TSXV: KDA) (“KDA Group” or the “Corporation”) announces that it has approved an amendment to its stock option plan (the ”Plan”) in order to increase the number of class A shares (“Common Shares”)

Condensed Consolidated Interim Financial Statements

Thetford Mines, December 11, 2017 – KDA Group Inc. (TSXV: KDA) (“KDA Group” or the “Corporation”) is pleased to announce the appointment of Mr. Marc Beaudoin as Chief Operating Officer of KDA Group and Chief Executive Officer of its subsidiary Pharmapar Inc. (“Pharmapar”), effective immediately.

Thetford Mines, June 29, 2017 – KDA Group Inc. (TSXV : KDA) (“KDA Group” or the “Corporation”) announced today the issuance of 250,000 Class A shares of its share capital to Joddes Limited within the context of an internal reorganization pursuant to which KDA Group acquired all the outstanding shares of its indirect subsidiary Biomed (2002) Inc., which was held at 90 % by Pharmapar, a KDA subsidiary, and at 10 % by Joddes Limited.